MedTrace Logo

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

NCT05943041 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-02-14

No results posted yet for this study

Summary

Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial

Conditions

Interventions

DRUG

GB104(Level 1)

One capsule QD oral administration for 28 days

DRUG

GB104(Level 2)

Three capsules QD oral administration for 28 days

DRUG

GB104(Level 3)

Five capsules QD oral administration for 28 days

Sponsors & Collaborators

  • GILongevity

    lead INDUSTRY

Principal Investigators

  • Woo Yong Lee, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-28
Primary Completion
2023-12-22
Completion
2023-12-22

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05943041 on ClinicalTrials.gov